Fulgent Genetics Inc
NASDAQ:FLGT

Watchlist Manager
Fulgent Genetics Inc Logo
Fulgent Genetics Inc
NASDAQ:FLGT
Watchlist
Price: 27.86 USD 0.25% Market Closed
Market Cap: 861.2m USD

Fulgent Genetics Inc
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Fulgent Genetics Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Fulgent Genetics Inc
NASDAQ:FLGT
Cash & Cash Equivalents
$117.6m
CAGR 3-Years
-11%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Cash & Cash Equivalents
$432m
CAGR 3-Years
-15%
CAGR 5-Years
-23%
CAGR 10-Years
13%
CVS Health Corp
NYSE:CVS
Cash & Cash Equivalents
$9.1B
CAGR 3-Years
-19%
CAGR 5-Years
0%
CAGR 10-Years
12%
Cigna Corp
NYSE:CI
Cash & Cash Equivalents
$6B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
10%
Laboratory Corporation of America Holdings
NYSE:LH
Cash & Cash Equivalents
$598.1m
CAGR 3-Years
13%
CAGR 5-Years
-2%
CAGR 10-Years
-2%
Guardant Health Inc
NASDAQ:GH
Cash & Cash Equivalents
$580m
CAGR 3-Years
54%
CAGR 5-Years
32%
CAGR 10-Years
N/A
No Stocks Found

Fulgent Genetics Inc
Glance View

Market Cap
859.6m USD
Industry
Health Care

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.

FLGT Intrinsic Value
18.12 USD
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Fulgent Genetics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
117.6m USD

Based on the financial report for Sep 30, 2025, Fulgent Genetics Inc's Cash & Cash Equivalents amounts to 117.6m USD.

What is Fulgent Genetics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
17%

Over the last year, the Cash & Cash Equivalents growth was 103%. The average annual Cash & Cash Equivalents growth rates for Fulgent Genetics Inc have been -11% over the past three years , 17% over the past five years .

Back to Top